Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Extensive Stage Small Cell Lung Cancer 1Cardiotoxicity 1Burkitt Lymphoma 1

Interventions

oblimersen 1Razoxane 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Exercise 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cardiotoxicity × oblimersen × Clear all
NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡